Browsing Tag
OBODENCE
1 post
The inside story behind Samsung Bioepis’ European biosimilar takeover
Samsung Bioepis reclaims control of BYOOVIZ in Europe from Biogen, launching its own brand with a PFS version due in 2026. Read what this means for biosimilars.